Evidence map›Paper›PMID 29484519›Full record

ArticleClinical & experimental metastasis2017

Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example.

Barbara Fingleton, Kelly Lange, Beth Caldwell, Katherine V Bankaitis, Board of the Metastasis Research Society

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Barbara FingletonDepartment of Pharmacology, Vanderbilt University, 771 PRB, 2220 Pierce Ave, Nashville, TN, 37233-6480, USA. barbara.fingleton@vanderbilt.edu.ORCID 0000-0003-1132-0782
Kelly LangeMETAvivor Research and Support Inc., Annapolis, MD, USA.
Beth CaldwellMET UP, Oakland, CA, USA.
Katherine V BankaitisMetastasis Research Society, Tampa, USA.
Board of the Metastasis Research Society

Funding

Mechanisms that impact metastatic progression of triple negative breast cancerI01BX003374 · VA · BIRMINGHAM VA MEDICAL CENTER · PI SAMANT, RAJEEV S · 2017 to 2024
–
BLRD VA I01 BX003374
6 · The paper itself

Abstract

This commentary was written as a collaboration between the Board of the Metastasis Research Society and two patients with metastatic breast cancer. It was conceived in response to how preclinical scientific research is sometimes presented to non-scientists in a way that can cause stress and confusion. Translation of preclinical findings to the clinic requires overcoming multiple barriers. This is irrespective of whether the findings relate to exciting responses to new therapies or problematic effects of currently used therapies. It is important that these barriers are understood and acknowledged when research findings are summarized for mainstream reporting. To minimize confusion, patients should continue to rely on their oncology care team to help them interpret whether research findings presented in mainstream media have relevance for their individual care. Researchers, both bench and clinical, should work together where possible to increase options for patients with metastatic disease, which is still in desperate need of effective therapeutic approaches.

Indexed as

Biomedical ResearchDecision MakingEvidence-Based MedicineTranslational Research, BiomedicalBreast NeoplasmsDisease ProgressionFemaleHumansMetastatic progressionNeoadjuvant chemotherapyRelapseSurvival

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.